PT2169073E - Vectores para a preparação de composições imunoterapêuticas - Google Patents

Vectores para a preparação de composições imunoterapêuticas Download PDF

Info

Publication number
PT2169073E
PT2169073E PT91765313T PT09176531T PT2169073E PT 2169073 E PT2169073 E PT 2169073E PT 91765313 T PT91765313 T PT 91765313T PT 09176531 T PT09176531 T PT 09176531T PT 2169073 E PT2169073 E PT 2169073E
Authority
PT
Portugal
Prior art keywords
retroviral
vector
response
cis
origin
Prior art date
Application number
PT91765313T
Other languages
English (en)
Inventor
Pierre Charneau
Veronique Zennou
Hueseyin Firat
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut
Publication of PT2169073E publication Critical patent/PT2169073E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
PT91765313T 1999-10-11 1999-10-11 Vectores para a preparação de composições imunoterapêuticas PT2169073E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99402492A EP1092779B1 (en) 1999-10-11 1999-10-11 Lentiviral vectors for the preparation of immunotherapeutical compositions

Publications (1)

Publication Number Publication Date
PT2169073E true PT2169073E (pt) 2014-02-20

Family

ID=8242139

Family Applications (4)

Application Number Title Priority Date Filing Date
PT99402492T PT1092779E (pt) 1999-10-11 1999-10-11 Vectores lentivíricos para a preparação de composições imunoterapêuticas
PT91765313T PT2169073E (pt) 1999-10-11 1999-10-11 Vectores para a preparação de composições imunoterapêuticas
PT00972845T PT1222300E (pt) 1999-10-11 2000-10-10 Vectores lentiviricos para a preparacao de composicoes imunoterapeuticas
PT06001198T PT1650309E (pt) 1999-10-11 2000-10-10 Vectores lentivirais para a preparação de composições imunoterapêuticas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT99402492T PT1092779E (pt) 1999-10-11 1999-10-11 Vectores lentivíricos para a preparação de composições imunoterapêuticas

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT00972845T PT1222300E (pt) 1999-10-11 2000-10-10 Vectores lentiviricos para a preparacao de composicoes imunoterapeuticas
PT06001198T PT1650309E (pt) 1999-10-11 2000-10-10 Vectores lentivirais para a preparação de composições imunoterapêuticas

Country Status (15)

Country Link
US (3) US7968332B2 (pt)
EP (4) EP2169073B1 (pt)
JP (2) JP4663943B2 (pt)
CN (2) CN1840204B (pt)
AT (3) ATE449858T1 (pt)
AU (3) AU785060B2 (pt)
CA (1) CA2387182C (pt)
CY (4) CY1105149T1 (pt)
DE (3) DE69941703D1 (pt)
DK (4) DK1092779T3 (pt)
ES (4) ES2447115T3 (pt)
HK (2) HK1049861B (pt)
IL (2) IL148901A0 (pt)
PT (4) PT1092779E (pt)
WO (1) WO2001027300A1 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777909B1 (fr) * 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
EP2169073B1 (en) 1999-10-11 2013-11-13 Institut Pasteur Vector for the preparation of immunotherapeutical compositions
ES2377721T3 (es) 1999-10-12 2012-03-30 Institut Pasteur ADN de triple hélice lentiviral, y vectores y células recombinantes que contienen ADN de triple hélice lentiviral
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
EP1412493B1 (en) 2001-08-02 2011-10-05 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
IL161229A0 (en) 2001-10-02 2004-09-27 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications.
FR2870126B1 (fr) * 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
EP1712241A1 (en) 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Composition for treating cancer adapted for intra-tumoral administration and uses thereof
US8158413B2 (en) * 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
EP1739092A1 (en) 2005-06-28 2007-01-03 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Peptidic antagonists of class III semaphorins/neuropilins complexes
EP1748067A1 (en) 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
US9150628B2 (en) 2005-11-14 2015-10-06 Centre National De La Recherche Scientifique (Cnrs) PARP inhibitors
US8765462B2 (en) 2007-05-04 2014-07-01 University Health Network IL-12 immunotherapy for cancer
EP2185192B1 (en) * 2007-08-03 2018-10-31 Institut Pasteur Lentiviral gene transfer vectors and their medicinal applications
DK2385107T3 (en) 2010-05-03 2016-12-12 Pasteur Institut Lentiviral vector-based immunological compounds against malaria
EP2666477A1 (en) 2012-05-23 2013-11-27 Theravectys Lentiviral vectors containing an MHC class I promoter
EP3202897B1 (en) 2010-12-09 2020-04-15 Institut Pasteur Diagnostic use of a fusion polypeptide comprising a viral protein and a mgmt enzyme
US9638692B2 (en) 2011-12-09 2017-05-02 Institut Pasteur Multiplex immuno screening assay
US20150182617A1 (en) 2012-07-25 2015-07-02 Theravectys Glycoproteins for pseudotyping lentivectors
EP3009144A1 (en) 2014-10-15 2016-04-20 Theravectys Lentiviral vectors for inducing CD4+ and CD8+ immune responses in vaccination of humans
WO2015063706A1 (en) 2013-10-31 2015-05-07 Theravectys Lentiviral vectors for expression of hiv-1 antigens
WO2015097650A1 (en) 2013-12-23 2015-07-02 Theravectys Lyophilized lentiviral vector particles, compositions and methods
JP6612237B2 (ja) 2014-01-27 2019-11-27 テラベクティ ヒトｔリンパ向性ウイルス１型に対する免疫応答を生成するためのレンチウイルスベクター
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
CA2956385A1 (en) 2014-07-25 2016-01-28 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
EP3031923A1 (en) 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
EP3410849B1 (en) 2016-02-05 2023-07-05 Institut Pasteur Use of inhibitors of adam12 as adjuvants in tumor therapies
EP3211003A1 (en) 2016-02-24 2017-08-30 Institut Pasteur T cell receptors from the hiv-specific repertoire, means for their production and therapeutic uses thereof
EP3276006A1 (en) 2016-07-27 2018-01-31 Theravectys Lentiviral vectors for expression of hepatitis b virus (hbv) antigens
EP3357506A1 (en) 2017-02-02 2018-08-08 Institut Pasteur Multiple malaria pre-erythrocytic antigens and their use in the elicitation of a protective immune response in a host
EP3357504A1 (en) 2017-02-02 2018-08-08 Institut Pasteur Functional screening of antigenic polypeptides - use for the identification of antigens eliciting a protective immune response and for the selection of antigens with optimal protective activity
EP3648776A4 (en) 2017-07-06 2021-04-07 The Medical College of Wisconsin, Inc. NEW IN VITRO AND IN VIVO ENRICHMENT STRATEGY TARGETING CHS-DERIVED LYMPHOCYTES TRANSDUCED BY A VECTOR FOR THE THERAPY OF DISORDERS
US20200331975A1 (en) 2017-10-20 2020-10-22 Institut Curie Dap10/12 based cars adapted for rush
US20200283485A1 (en) 2017-10-20 2020-09-10 Institut Curie Hook fusion protein for regulating the cellular trafficking of a target protein
CN108118070A (zh) * 2018-01-15 2018-06-05 南京驯鹿医疗技术有限公司 一种慢病毒制备方法
CN108588028B (zh) * 2018-04-26 2021-11-09 中国人民解放军军事科学院军事医学研究院 一种靶向cdkn2a的cic细胞模型及其制备方法
CA3136252A1 (en) 2019-05-10 2020-11-19 Francesca DI NUNZIO Live imaging system to visualize the retro-transcribed viral dna genome
CA3182333A1 (en) 2020-05-20 2021-11-25 Institut Curie Single domain antibodies and their use in cancer therapies
WO2022167831A1 (en) 2021-02-02 2022-08-11 Institut Pasteur Sars-cov-2 immunogenic compositions, vaccines, and methods
CN117120085A (zh) 2020-07-15 2023-11-24 巴斯德研究所 Sars-cov-2免疫原性组合物、疫苗和方法
CA3185952A1 (en) 2020-07-15 2022-01-20 Pierre Charneau Sars-cov-2 immunogenic compositions, vaccines, and methods
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
US20240053339A1 (en) 2020-09-21 2024-02-15 Theravectys High throughput methods and products for sars-cov-2 sero-neutralization assay
US20230374542A1 (en) 2020-10-07 2023-11-23 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
EP3984548A1 (en) 2020-10-16 2022-04-20 Institut Pasteur Generation of lentiviral vectors enabling routing antigens to mhc-ii pathway and inducing cd4+ and cd8+ t-cell responses immune response in a host
WO2022079270A1 (en) 2020-10-16 2022-04-21 Université D'aix-Marseille Anti-gpc4 single domain antibodies
EP4277934A1 (en) 2021-01-14 2023-11-22 Institut Curie Her2 single domain antibodies variants and cars thereof
CA3209285A1 (en) 2021-03-12 2022-09-15 Pierre Charneau Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host
WO2023084094A1 (en) 2021-11-15 2023-05-19 Theravectys Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers
WO2024023135A1 (en) 2022-07-27 2024-02-01 Theravectys Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers
WO2024084041A2 (en) 2022-10-21 2024-04-25 Institut Pasteur Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009271A1 (en) * 1988-03-21 1989-10-05 Viagene, Inc. Recombinant retroviruses
GB9213559D0 (en) * 1992-06-25 1992-08-12 Smithkline Beecham Biolog Vaccines
JPH06261764A (ja) 1993-02-17 1994-09-20 Wisconsin Alumni Res Found 混合型ｌｔｒ含有超複合型レトロウイルス及びその使用方法
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
AU723313B2 (en) * 1996-03-05 2000-08-24 Regents Of The University Of California, The Recombinant live feline immunodeficiency virus and proviral DNA vaccines
JP2001513643A (ja) * 1997-03-06 2001-09-04 ウーベルラ、クラウス レンチウイルスをベースとするベクター及びベクター系
AU7158398A (en) 1997-04-17 1998-11-11 Regents Of The University Of California, The Use of lentiviral vectors for antigen presentation in dendritic cells
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
DE69837896T2 (de) * 1997-10-10 2008-02-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptidagonisten von karzinoembryonalem Antigen (CEA)
IL136113A0 (en) * 1997-11-14 2001-05-20 Euro Celtique Sa Modified antibodies with enhanced ability to elicit an anti-idiotype response
FR2777909B1 (fr) * 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US6555342B1 (en) * 1998-06-03 2003-04-29 Uab Research Foundation Fusion protein delivery system and uses thereof
US7622300B2 (en) * 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
GB9825524D0 (en) 1998-11-20 1999-01-13 Oxford Biomedica Ltd Vector
EP2169073B1 (en) 1999-10-11 2013-11-13 Institut Pasteur Vector for the preparation of immunotherapeutical compositions
ES2377721T3 (es) 1999-10-12 2012-03-30 Institut Pasteur ADN de triple hélice lentiviral, y vectores y células recombinantes que contienen ADN de triple hélice lentiviral
US20030194392A1 (en) 2002-04-10 2003-10-16 Pierre Charneau Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
US8158413B2 (en) 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine

Also Published As

Publication number Publication date
DK1650309T3 (da) 2009-11-30
CY1114819T1 (el) 2016-12-14
CN1379820A (zh) 2002-11-13
CA2387182A1 (en) 2001-04-19
CN1840204A (zh) 2006-10-04
DK1222300T3 (da) 2006-09-18
DE69941703D1 (de) 2010-01-07
AU785060B2 (en) 2006-09-14
PT1222300E (pt) 2006-09-29
EP2169073B1 (en) 2013-11-13
CN1379820B (zh) 2011-04-13
AU2006252062A1 (en) 2007-01-18
EP1222300B1 (en) 2006-05-17
EP1092779A1 (en) 2001-04-18
HK1093523A1 (en) 2007-03-02
US7968332B2 (en) 2011-06-28
ES2337429T3 (es) 2010-04-23
IL148901A0 (en) 2002-09-12
DK1092779T3 (da) 2010-02-15
US20130157357A1 (en) 2013-06-20
HK1049861A1 (en) 2003-05-30
US8652807B2 (en) 2014-02-18
US8349606B2 (en) 2013-01-08
CY1110551T1 (el) 2015-04-29
ES2262545T3 (es) 2006-12-01
CY1105149T1 (el) 2010-03-03
DE60028066D1 (de) 2006-06-22
EP2169073A1 (en) 2010-03-31
DE60028066T2 (de) 2007-01-18
IL204703A0 (en) 2010-11-30
AU1143501A (en) 2001-04-23
ES2332930T3 (es) 2010-02-15
AU2010203111B2 (en) 2012-01-19
EP1222300A1 (en) 2002-07-17
CA2387182C (en) 2010-12-21
US20110250650A1 (en) 2011-10-13
DE60042903D1 (de) 2009-10-15
JP2003511080A (ja) 2003-03-25
ES2447115T3 (es) 2014-03-11
CN1840204B (zh) 2011-09-07
WO2001027300A1 (en) 2001-04-19
EP1092779B1 (en) 2009-11-25
ATE326541T1 (de) 2006-06-15
JP4663943B2 (ja) 2011-04-06
EP1650309B1 (en) 2009-09-02
PT1650309E (pt) 2009-11-18
AU2010203111A1 (en) 2010-08-12
US20040081636A1 (en) 2004-04-29
JP2011078420A (ja) 2011-04-21
JP5265643B2 (ja) 2013-08-14
ATE449858T1 (de) 2009-12-15
PT1092779E (pt) 2010-01-19
EP1650309A1 (en) 2006-04-26
DK2169073T3 (da) 2014-02-10
ATE441721T1 (de) 2009-09-15
AU2006252062B2 (en) 2010-04-22
HK1049861B (zh) 2006-12-22
CY1110611T1 (el) 2015-04-29

Similar Documents

Publication Publication Date Title
PT2169073E (pt) Vectores para a preparação de composições imunoterapêuticas
CA2092195A1 (en) Retroviral packaging cell line
EP0837928A4 (en) COMPOSITIONS OF RECOMBINED POXVIRUS-CYTOMEGALOVIRUS AND THEIR USE
CA2253636A1 (en) Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof
WO2003004620A3 (en) Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1084261B8 (en) Recombinant venezuelan equine encephalitis virus vaccine
EP1409694A4 (en) POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF
EP0775746A3 (en) Coccidiosis poultry vaccine
WO2000063406A3 (en) Adenoviral vectors having nucleic acids encoding immunomodulatory molecules
WO2004035799A3 (de) Virale vektoren und deren verwendung für die gentherapie
CA2002318A1 (en) Dna encoding ¬lys46,asp97,asp113|and¬lys46,asp97,asp137|thaumatin i polypeptides
EP1840209A3 (en) Adeno-associated virus vectors and use thereof
WO2005027844A3 (en) Dna vaccine compositions and methods of use
EP1449510A4 (en) HAIR CARE PRODUCTS
AU7528087A (en) Immunogenic fraction active against bilharzioses, its preparation, and immunizing compositions containing it
CA2002403A1 (en) Injury-stimulated dna-sequence from solanum tuberosum and its use
WO2004003010A3 (en) Nuclear hormone receptor ligano-binding domain containing protein
WO1999014333A3 (en) Improved method of production of pneumococcal surface proteins
ES2008391A6 (es) Un metodo para producir isopenicilina n sintetasa.
Wood Private Groups Face Off in Brazilian Petrochemical Battle
Komolikov et al. High Strength Ceramics of ZrO sub 2 Partially Stabilized by Yb sub 2 O sub 3
WO2000077232A8 (en) Promoters from atlantic salmon
WO2001027297A3 (en) VERSATILE rpL34 PROMOTER ELEMENTS AND USE THEREOF
BR9908649A (pt) Composição de vacina
WO2000027982A3 (en) Bleaching compositions